Teriparatide

10mg Vial

2 September 2026Updated 2 September 2026

Teriparatide

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Teriparatide.

Create free account Member login

Full range of benefits for Teriparatide

Stimulates osteoblast activity to increase new bone formation

Increases bone mineral density at the lumbar spine and hip

Shown in clinical trials to reduce risk of vertebral fractures

Improves trabecular bone microarchitecture and strength

Raises biochemical markers of bone formation (eg, P1NP)

Effective for glucocorticoid-induced and severe osteoporosis

May accelerate healing of certain osteoporotic fractures

Onset of bone-building effects is faster than many antiresorptives

Often used as a finite-course therapy followed by maintenance agents

Daily subcutaneous dosing provides predictable pharmacologic effect

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 15 known interactions

Synergistic(3)Compatible(4)Monitor(4)Avoid(4)

Not recommended for concurrent use

Bisphosphonates

Concurrent bisphosphonate use may blunt teriparatide's anabolic effect on bone; clinicians should evaluate timing and consider sequencing rather than routine coadministration.

High-dose systemic glucocorticoids

Chronic high-dose glucocorticoids increase fracture risk and can reduce anabolic response to teriparatide, requiring careful risk–benefit assessment and monitoring.

Radionuclide bone therapies (e.g., samarium, strontium therapies)

Previous or concurrent radionuclide treatment involving the skeleton can alter bone remodelling dynamics and may increase safety concerns, so combine only after specialist review.

High-dose fluoride (e.g., sodium fluoride therapy)

Fluoride can change bone structure and quality and may interact adversely with anabolic bone agents, so concurrent use with teriparatide should be approached with caution.

All interaction categories

Synergistic (3)

Calcitriol (active vitamin D): Supports intestinal calcium absorption and helps prevent teriparatide-associated hypocalcaemia while facilitating bone mineralization during anabolic therapy.
Oral calcium supplements: Provide the mineral substrate required for new bone formation and reduce the risk of symptomatic hypocalcaemia when initiating teriparatide.
Denosumab (RANKL inhibitor): When used concurrently or in certain sequential regimens, denosumab plus teriparatide has been shown in studies to produce greater increases in BMD than either agent alone.

Compatible (4)

Levothyroxine: No clinically meaningful pharmacokinetic interaction with teriparatide; standard thyroid monitoring remains appropriate.
Statins: No direct interaction expected with teriparatide and may be continued for cardiovascular risk management without dose adjustment for the peptide.
Analgesics / NSAIDs (e.g., paracetamol, ibuprofen): Symptomatic pain treatments do not interact significantly with teriparatide and are generally compatible with therapy.
Proton pump inhibitors: Generally compatible with teriparatide although clinicians should consider effects on calcium absorption and address calcium/vitamin D adequacy if indicated.

Monitor (4)

Thiazide diuretics: Thiazides reduce urinary calcium excretion and can potentiate teriparatide-associated hypercalcaemia, so monitor serum calcium after initiation or dose changes.
Loop diuretics: Loop diuretics increase urinary calcium loss and alter fluid/electrolyte balance, requiring monitoring of calcium and renal function during teriparatide therapy.
Lithium: Lithium affects parathyroid function and calcium homeostasis, and combined use with teriparatide warrants monitoring of serum calcium and lithium levels.
Digoxin: Teriparatide-associated hypercalcaemia can increase the risk of digoxin toxicity, so monitor digoxin levels and cardiac status if coadministered.

Avoid (4)

Bisphosphonates: Concurrent bisphosphonate use may blunt teriparatide's anabolic effect on bone; clinicians should evaluate timing and consider sequencing rather than routine coadministration.
High-dose systemic glucocorticoids: Chronic high-dose glucocorticoids increase fracture risk and can reduce anabolic response to teriparatide, requiring careful risk–benefit assessment and monitoring.
Radionuclide bone therapies (e.g., samarium, strontium therapies): Previous or concurrent radionuclide treatment involving the skeleton can alter bone remodelling dynamics and may increase safety concerns, so combine only after specialist review.
High-dose fluoride (e.g., sodium fluoride therapy): Fluoride can change bone structure and quality and may interact adversely with anabolic bone agents, so concurrent use with teriparatide should be approached with caution.